<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pretreatment evaluation and staging of non-Hodgkin lymphomas</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pretreatment evaluation and staging of non-Hodgkin lymphomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pretreatment evaluation and staging of non-Hodgkin lymphomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Non-Hodgkin lymphomas (NHL) are a diverse group of lymphoid malignancies that vary according to the underlying pathobiology, natural history, preferred treatment, and prognosis. Pretreatment evaluation for a patient with a newly diagnosed NHL must establish the histologic subtype  (<a class="graphic graphic_table graphicRef110240" href="/z/d/graphic/110240.html" rel="external">table 1</a>), disease stage (ie, extent and sites of disease)  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 2</a>), and medical fitness. </p><p>This topic addresses the general pretreatment evaluation of a patient with a newly diagnosed NHL, including clinical and laboratory studies, imaging, and disease staging. Importantly, certain aspects of the pretreatment evaluation vary according to the specific subtype of NHL; such details are presented with the initial treatment of the specific lymphoma category. </p><p class="headingAnchor" id="H2039928919"><span class="h1">CLINICAL AND LABORATORY EVALUATION</span></p><p class="headingAnchor" id="H2859064105"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The history should consider constitutional symptoms (eg, unexplained fevers, sweats, unintended weight loss) and neurologic complaints (eg, headache, altered vision, motor or sensory complaints). Symptoms related to heart, lung, kidney, and liver disease and other comorbid conditions should be assessed. </p><p>Physical examination should evaluate lymph node-bearing areas (including Waldeyer's ring), liver, and spleen and should screen for neurologic abnormalities.</p><p class="headingAnchor" id="H2939154942"><span class="h2">Medical fitness</span><span class="headingEndMark"> — </span>Fitness for treatment is assessed by clinical evaluation and performance status. For some patients, use of an assessment instrument for comorbid illnesses or geriatric consultation may be helpful for judging fitness.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – Performance status is a measure of a patient's functional capacity. Assessment of performance status may affect the choice of treatment and is associated with outcomes for many lymphomas. </p><p></p><p class="bulletIndent1">Karnofsky performance status (KPS) and the Eastern Cooperative Oncology Group (ECOG) performance status are most commonly used as instruments to judge performance status  (<a class="graphic graphic_table graphicRef58785 graphicRef72901" href="/z/d/graphic/58785.html" rel="external">table 3A-B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Comorbid conditions</strong> – For patients with significant conditions identified by clinical evaluation, an instrument for assessing the severity of comorbid illnesses, such as the Charlson comorbidity index  (<a class="graphic graphic_table graphicRef65323" href="/z/d/graphic/65323.html" rel="external">table 4</a>), can be useful.</p><p></p><p class="bulletIndent1">Comprehensive geriatric assessment may be helpful for judging fitness of certain older patients. (See  <a class="medical medical_review" href="/z/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p></p><p class="headingAnchor" id="H1150653658"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory studies for patients with newly diagnosed NHL should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete blood count (CBC) and blood smear</strong> – CBC, including differential count and evaluation of the blood smear.</p><p></p><p class="bulletIndent1">The presence of atypical cells on the blood smear  (<a class="graphic graphic_picture graphicRef65023" href="/z/d/graphic/65023.html" rel="external">picture 1</a>) suggests lymphomatous involvement of bone marrow, which is most common with indolent lymphomas, such as follicular lymphoma. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum chemistries</strong> – Chemistry studies should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Electrolytes</strong> – Including calcium, phosphorus, and uric acid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney function tests</strong> – Blood urea nitrogen (BUN) and creatinine.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver function tests</strong> – Including alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), and albumin.</p><p></p><p class="bulletIndent1">Kidney function tests are important for choosing treatment, since many agents are nephrotoxic and/or excreted through the kidney  (<a class="graphic graphic_table graphicRef54722" href="/z/d/graphic/54722.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/z/d/html/2834.html" rel="external">"Nephrotoxicity of chemotherapy and other cytotoxic agents"</a> and  <a class="medical medical_review" href="/z/d/html/114914.html" rel="external">"Nephrotoxicity of molecularly targeted agents and immunotherapy"</a>.)</p><p></p><p class="bulletIndent1">High levels of uric acid, calcium, potassium, phosphorus, and serum creatinine may indicate spontaneous tumor lysis syndrome (TLS), which is more common with aggressive tumors (eg, diffuse large B cell lymphoma [DLBCL], Burkitt lymphoma, high-grade B cell lymphoma with <em>MYC</em> and <em>BCL2</em> and/or <em>BCL6</em> gene rearrangements); TLS requires urgent management before initiating chemotherapy, because treatment will further exacerbate TLS. (See  <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent1">Elevated BUN or creatinine may also indicate bilateral ureteral obstruction caused by retroperitoneal nodes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum protein electrophoresis (SPEP) and/or serum viscosity </strong>–<strong> </strong>SPEP, serum viscosity, and/or beta-2 globulin should be obtained in<strong> </strong>selected cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SPEP</strong> – Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) should have a pretreatment SPEP to document a circulating monoclonal paraprotein or hypogammaglobulinemia, which may be associated with increased risk for infection. Patients with lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM) may have a serum immunoglobulin (Ig) M paraprotein. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a> and  <a class="medical medical_review" href="/z/d/html/4513.html" rel="external">"Clinical features and diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serum viscosity</strong> – Serum viscosity may be increased due to elevated serum IgM (eg, in LPL/WM) or, rarely, elevated IgA. Viscosity should be evaluated urgently in patients with symptoms suspicious of hyperviscosity (eg, blurry vision, headache, vertigo). (See  <a class="medical medical_review" href="/z/d/html/6657.html" rel="external">"Epidemiology, pathogenesis, clinical manifestations, and diagnosis of Waldenström macroglobulinemia", section on 'Hyperviscosity syndrome'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Beta-2 microglobulin</strong> – For patients with follicular lymphoma, beta-2 microglobulin is used for certain prognostic instruments. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'PRIMA prognostic index (PRIMA-PI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV </strong>– All patients should be tested for HIV, as documentation of HIV infection may affect diagnosis, treatment, and prognosis. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p class="bulletIndent1">In patients with HIV infection, systemic NHL and primary central nervous system (CNS) lymphoma are AIDS-defining malignancies. (See  <a class="medical medical_review" href="/z/d/html/4726.html" rel="external">"HIV-related lymphomas: Epidemiology, risk factors, and pathobiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis serologies</strong> – Testing for hepatitis B or hepatitis C is important for selected patients, as the underlying infection or its hepatic and hematologic complications can affect NHL management.</p><p></p><p class="bulletIndent1">Treatment of the viral hepatitis should be considered before or at the time of initiating treatment for the lymphoma. (See  <a class="medical medical_review" href="/z/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management", section on 'Patients receiving immunosuppressive therapy'</a> and  <a class="medical medical_review" href="/z/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Deciding when to treat'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis B</strong> – All patients who may receive <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> should be tested for hepatitis B because of the risk of hepatitis B reactivation. Testing includes hepatitis B surface antigen (HBsAg) and antibodies against hepatitis B core antigen (anti-HBc); for patients who are HBsAg positive, testing for HBeAg, anti-HBe, and an HBV DNA level should be evaluated. </p><p></p><p class="bulletIndent2">Antiviral therapy for infected patients should start before treatment commences and continue for months after chemotherapy [<a href="#rid1">1,2</a>]. Reactivation of hepatitis B virus during chemotherapy, which occurs in 20 to 50 percent of HBsAg carriers, can be associated with a high mortality despite antiviral treatment [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent2">Patients who are not infected may benefit from hepatitis B vaccination. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hepatitis C</strong> – Some experts test all patients for hepatitis C, while some limit testing to patients with marginal zone lymphoma. Serologic testing for hepatitis C should include both antibody testing and hepatitis C RNA assays. (See  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection", section on 'Diagnostic techniques'</a>.)</p><p></p><p class="bulletIndent1">Infection with hepatitis B or hepatitis C may have a causal relationship with certain cases of NHL [<a href="#rid5">5-8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy testing</strong> – All women of child-bearing potential should have pregnancy testing. </p><p></p><p class="bulletIndent1">Fertility preservation is discussed below. (See <a class="local">'Fertility preservation'</a> below.)</p><p></p><p class="headingAnchor" id="H463623477"><span class="h1">CLINICAL TESTING</span><span class="headingEndMark"> — </span>Heart function should be evaluated for patients with known heart disease and for those who may receive cardiotoxic treatments. Bone marrow examination or evaluation for nervous system involvement is performed in selected patients. </p><p class="headingAnchor" id="H2253008839"><span class="h2">Cardiac function</span><span class="headingEndMark"> — </span>Echocardiogram or radionuclide ventriculogram (RVG or MUGA) should be used to assess cardiac ejection fraction if the patient may be treated with an anthracycline or receive mediastinal irradiation. Cardiac function testing may not be necessary if the patient is young, has no history of heart disease, and is going to get a relatively small dose of an anthracycline. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H2255701248"><span class="h2">Bone marrow examination</span><span class="headingEndMark"> — </span>Bone marrow (BM) examination is needed in only limited circumstances, because positron emission tomography (PET)/computed tomography (CT) is sensitive for detecting BM involvement by NHL.</p><p>We perform a unilateral BM examination, including microscopy, special stains, flow cytometry, and/or molecular studies  (<a class="graphic graphic_table graphicRef82481" href="/z/d/graphic/82481.html" rel="external">table 6</a>) to:</p><p class="bulletIndent1"><span class="glyph">●</span>Exclude systemic disease in a patient with apparent stage I disease </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluate possible discordant histology (eg, transformation of follicular lymphoma)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Investigate abnormal blood counts in patients without an alternative explanation</p><p></p><p>For most NHL histologic subtypes, the ability of PET/CT to accurately detect BM involvement is not well-defined [<a href="#rid9">9,10</a>]. However, for diffuse large B cell lymphoma (DLBCL), PET is highly specific for detecting lymphomatous BM involvement; nevertheless, normal BM on PET does not exclude BM involvement by DLBCL because it may miss diffuse, low-volume (10 to 20 percent of marrow) disease. In a meta-analysis that included data from seven studies with a total of 654 patients with newly diagnosed DLBCL, PET had moderate sensitivity (88.7 percent) and high specificity (99.8 percent) for detecting BM involvement [<a href="#rid11">11</a>]. Approximately 3 percent of patients with involvement on BM biopsy had a negative PET, while 13 percent with involvement on PET had a negative BM biopsy. </p><p>The role of BM biopsy for response assessment in most NHL is also very limited [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3483647838"><span class="h2">Central nervous system (CNS)</span><span class="headingEndMark"> — </span>CNS involvement should be investigated for patients with abnormal findings on neurologic examination, new neurologic symptoms, or those with certain histologic categories or clinical features. </p><p>A multimodal approach can detect both parenchymal and leptomeningeal involvement. We obtain magnetic resonance imaging (MRI; with and without gadolinium contrast) and lumbar puncture (LP), but a CT with intravenous contrast is acceptable for patients who cannot undergo MRI because of an implanted metallic device. </p><p>LP, including cytology and flow cytometry, should be performed in patients who have a substantial risk of involvement of the CNS, based on histologic category or certain clinical features  (<a class="graphic graphic_table graphicRef54470" href="/z/d/graphic/54470.html" rel="external">table 7</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Highly aggressive NHL</strong> – Examples of highly aggressive NHL associated with increased risk for CNS involvement include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Burkitt lymphoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adult T cell leukemia-lymphoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High grade lymphoma with </strong><strong><em>MYC</em></strong><strong> and </strong><strong><em>BCL2</em></strong><strong> and/or </strong><strong><em>BCL6</em></strong><strong> gene rearrangement</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV-positive NHL</strong> – Most types of HIV-related NHL are associated with increased risk for CNS involvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher-risk for CNS involvement</strong> – Patients with DLBCL, peripheral T cell lymphoma (PTCL), grade 3b follicular lymphoma, or mantle cell lymphoma with one of the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Epidural, bone marrow, testicular, or paranasal sinus involvement</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥2 extranodal disease sites </p><p></p><p class="bulletIndent1">Increased risk for CNS involvement by NHL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4720.html" rel="external">"Secondary central nervous system lymphoma: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'Central nervous system (CNS) evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h2">Fertility preservation</span><span class="headingEndMark"> — </span>Fertility preservation, including sperm or fertilized ovum banking, should be discussed with patients of childbearing age prior to initiating treatment. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">IMAGING</span></p><p class="headingAnchor" id="H520759233"><span class="h2">Choice of imaging modality</span><span class="headingEndMark"> — </span>The choice of imaging modality is influenced by the histologic subtype of NHL: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Positron emission tomography (PET)/computed tomography (CT)</strong> – Whole-body PET, using 18F-fluorodeoxyglucose (<sup>18</sup>F-FDG), with concurrent CT is preferred for evaluation and staging of most NHL subtypes [<a href="#rid13">13-17</a>]. </p><p></p><p class="bulletIndent1">In special situations (eg, blood vessel compression/thrombosis, lymphadenopathy close to bowel), a dedicated contrast-enhanced CT or other studies may be needed in addition to PET/CT. (See <a class="local">'Evaluation of specific sites'</a> below.)</p><p></p><p class="bulletIndent1">Although most categories of nodal NHL are FDG-avid, certain histologic subtypes are variably FDG-avid or non-avid [<a href="#rid9">9,10</a>]. PET has inconsistent usefulness for these and other indolent lymphomas, but it may be helpful in some circumstances (eg, to identify a preferred biopsy site if aggressive transformation is suspected). Examples of variably FDG-avid categories include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphoplasmacytic lymphoma (LPL)/Waldenström macroglobulinemia (WM)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mycosis fungoides (MF)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Marginal zone lymphoma (MZL)</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Computed tomography</strong> – CT of chest, abdomen, and pelvis with intravenous contrast or oral contrast is used to define the extent of disease for FDG-non-avid or variably FDG-avid histologies (described above). CT of the neck should be performed, as clinically indicated.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Positron emission tomography (PET)</span><span class="headingEndMark"> — </span>PET is used for initial staging of most types of NHL and is a key component of assessing response to therapy. </p><p>PET combined with near-simultaneous CT identifies lymphoma-related uptake for many histologic categories (discussed above) and can help to distinguish it from non-lymphomatous activity (eg, infection, inflammation). PET is highly sensitive and specific for detecting NHL in nodal and extranodal sites and it has variable reliability for detecting bone marrow involvement, as discussed above. (See <a class="local">'Bone marrow examination'</a> above.)</p><p>Standardized uptake value (SUV) is a semi-quantitative method for assessing PET activity [<a href="#rid18">18</a>]. SUV analysis is useful because uptake of the radiolabeled tracer, 2-deoxy-2-[<sup>18</sup>F] fluoro-D-glucose (FDG), varies with the amount of injected FDG, patient size, and among different organs/tissues. For most histologic categories of NHL, uptake by involved lymph nodes and some locations (eg, Waldeyer's ring, certain extranodal sites) is generally greater than PET activity of the mediastinal blood pool and/or liver [<a href="#rid9">9</a>].</p><p>The use of PET for assessing response to treatment using the five-point (Deauville score) is incorporated into the Lugano criteria  (<a class="graphic graphic_table graphicRef97480" href="/z/d/graphic/97480.html" rel="external">table 8</a>) [<a href="#rid9">9,10</a>] and is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma", section on 'End-of-treatment PET'</a>.)</p><p>The following studies have investigated FDG-avidity of various NHL histologic subtypes:</p><p class="bulletIndent1"><span class="glyph">●</span>PET revealed at least one FDG-avid site in 718 of 766 patients (94 percent) in one study of patients with NHL or Hodgkin lymphoma [<a href="#rid19">19</a>]. The frequency of FDG-avidity varied by histologic subtype:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FDG-avid </strong>– FDG-avidity was present in all cases of Burkitt lymphoma, mantle cell lymphoma (MCL), nodal MZL, lymphoblastic lymphoma, and Hodgkin lymphoma. FDG-avidity was also high in patients with DLBCL (97 percent) and follicular lymphoma (FL; 95 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>FDG-variable </strong>– Lower rates of FDG-avidity were seen in T cell lymphoma (85 percent), CLL/SLL (83 percent) and extranodal MZL (55 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, PET detected disease in at least one location in 98 to 100 percent of patients with pathologically proven DLBCL, MCL, Hodgkin lymphoma, and FL, but it was less often able to detect disease in patients with MZL and peripheral T cell lymphoma [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study that used CT and/or MRI to confirm sites of involvement reported that PET identified &gt;97 percent of disease sites identified by CT or MRI in Hodgkin lymphoma and aggressive or highly aggressive NHL [<a href="#rid21">21</a>]. PET was less sensitive for the detection of lesions in the indolent NHL variants, with sensitivities of 91, 82, and 50 percent for FL, extranodal MZL of MALT tissue, and SLL/splenic marginal zone lymphoma, respectively.</p><p></p><p class="headingAnchor" id="H520759320"><span class="h2">Computed tomography (CT)</span><span class="headingEndMark"> — </span>Contrast-enhanced CT is often preferred for imaging variably FDG-avid or nonavid histologic subtypes [<a href="#rid9">9,10</a>]. For any histologic category, a dedicated contrast-enhanced CT can help to define the extent of disease in special situations, such as lymphadenopathy close to bowel or if there is compression or thrombosis of blood vessels. (See <a class="local">'Choice of imaging modality'</a> above.)</p><p>When CT is used for staging, the initial evaluation should include a contrast-enhanced CT scan of the chest, abdomen, and pelvis  (<a class="graphic graphic_diagnosticimage graphicRef59628" href="/z/d/graphic/59628.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef58932" href="/z/d/graphic/58932.html" rel="external">image 2</a>). A dedicated CT of the neck may be necessary for patients with cervical and/or supraclavicular nodal involvement on physical examination. </p><p>The report should include bidirectional measurements of the six largest nodes, nodal masses, or other lymphomatous lesions from different body regions [<a href="#rid9">9</a>]; involved nodes should have a longest diameter &gt;1.5 cm, and extranodal disease should have a longest diameter &gt;1 cm. Response to treatment can be assessed with subsequent imaging, using the six chosen lesions; other lesions (eg, cutaneous lesions, pleural or pericardial effusions, ascites) are generally considered non-measurable disease. </p><p class="headingAnchor" id="H19"><span class="h1">EVALUATION OF SPECIFIC SITES</span><span class="headingEndMark"> — </span>Specific evaluation of the gastrointestinal (GI) tract, liver, spleen, central nervous system (CNS), skeleton, or genitourinary (GU) tract is generally reserved for patients with symptoms or those at high risk for involvement of these sites.</p><p class="headingAnchor" id="H20"><span class="h2">Gastrointestinal tract</span><span class="headingEndMark"> — </span>Evaluation of the GI tract with imaging or endoscopy is indicated for patients with symptoms that suggest GI involvement  (<a class="graphic graphic_table graphicRef68593" href="/z/d/graphic/68593.html" rel="external">table 9</a>). </p><p>Endoscopic procedures are helpful in tumor localization and staging (eg, endoscopic ultrasound), detection of bleeding lesions, and in the obtaining of biopsy specimens in patients with GI lymphoma  (<a class="graphic graphic_picture graphicRef69159" href="/z/d/graphic/69159.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef72196" href="/z/d/graphic/72196.html" rel="external">picture 3</a>). CT  (<a class="graphic graphic_diagnosticimage graphicRef75825" href="/z/d/graphic/75825.html" rel="external">image 3</a> and <a class="graphic graphic_diagnosticimage graphicRef72998" href="/z/d/graphic/72998.html" rel="external">image 4</a>) is useful for simultaneously evaluating mucosal lesions and assessing the extraluminal extent of lesions and associated adenopathy. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas", section on 'Diagnostic evaluation'</a> and  <a class="medical medical_review" href="/z/d/html/4719.html" rel="external">"Mantle cell lymphoma: Initial management", section on 'Pretreatment evaluation'</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Liver and spleen</span><span class="headingEndMark"> — </span>Estimation of liver and spleen size (reported as centimeters below the costal margin in the midclavicular line) should be recorded with the initial physical examination of all patients with newly diagnosed NHL. Normal liver and spleen size do not rule out involvement, while hepatic or splenic enlargement in a patient with NHL is not always due to lymphoma.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> – For staging purposes in fluorodeoxyglucose (FDG)-avid histologies, liver involvement is determined by positron emission tomography (PET)/computed tomography (CT) demonstrating diffusely increased or focal FDG uptake, with or without focal or disseminated nodules [<a href="#rid9">9,10</a>]. Clinical hepatic enlargement alone, with or without abnormalities of liver function tests (LFTs), is not adequate. A percutaneous liver biopsy may be indicated if there are abnormalities of LFTs or liver imaging in patients with FDG-non-avid histologies who would otherwise have been classified as having stage I disease. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spleen</strong> – Splenic involvement in FDG-avid histologies is determined by PET/CT that reveals one of the following: homogeneous splenomegaly &gt;13 cm, diffuse infiltration with miliary lesions, focal nodular lesions, or a large solitary mass. Although some advocate fine needle aspiration biopsy of the spleen under radiologic guidance, this is generally not recommended, because of the increased risk of bleeding [<a href="#rid22">22,23</a>].</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Skeletal imaging</span><span class="headingEndMark"> — </span>For patients with bony pain and/or suspicion of a pathologic fracture, imaging with plain films, CT, and/or magnetic resonance imaging (MRI) should be performed, as clinically indicated. Routine bone imaging is generally not performed for asymptomatic patients with NHL.</p><p>For suspected spinal cord compression, urgent MRI of the entire spinal column is indicated, since multiple sites may be involved. (See  <a class="medical medical_review" href="/z/d/html/2819.html" rel="external">"Clinical features and diagnosis of neoplastic epidural spinal cord compression", section on 'Magnetic resonance imaging of the spine'</a>.)</p><p class="headingAnchor" id="H24"><span class="h2">Genitourinary tract</span><span class="headingEndMark"> — </span>The GU tract (eg, kidney, testis, ovary) is involved in approximately 10 percent of patients with NHL at initial diagnosis. </p><p>GU involvement is associated with increased risk for involvement of the CNS, as described above. (See <a class="local">'Central nervous system (CNS)'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney</strong> – The kidney is the most common site of GU involvement by NHL and is most often seen in patients with aggressive and highly aggressive histologic subtypes. </p><p></p><p class="bulletIndent1">Renal involvement is often seen on CT as multiple discrete masses, or diffuse infiltration causing renal enlargement  (<a class="graphic graphic_diagnosticimage graphicRef81101" href="/z/d/graphic/81101.html" rel="external">image 5</a>). Isolated masses are less common. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testis or ovary</strong> – Testis or ovary involvement usually occurs in patients with diffuse large B cell NHL (DLBCL). </p><p></p><p class="bulletIndent1">While most GU lesions are identified by CT, patients with an abnormality on testicular examination should have testicular ultrasound (US)  (<a class="graphic graphic_diagnosticimage graphicRef50490" href="/z/d/graphic/50490.html" rel="external">image 6</a>). Patients with testicular lymphoma should also have US of the apparently uninvolved testicle, to evaluate for contralateral disease. (See  <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">"Initial treatment of limited stage diffuse large B cell lymphoma", section on 'Testicular'</a>.)</p><p></p><p>Less common GU lesions include mural thickening of the bladder or a ureter, or mass lesions of the uterus, cervix, or prostate.</p><p class="headingAnchor" id="H29"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The Lugano classification is used for staging most patients with NHL, but some categories use distinctive staging systems. (See  <a class="medical medical_review" href="/z/d/html/4718.html" rel="external">"Primary cutaneous follicle center lymphoma"</a>.)</p><p>The Lugano classification focuses on the number of tumor sites (nodal and extranodal) and their location  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 2</a>) and was derived from the Ann Arbor staging system.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage I</strong> – Lymphoma involving a single lymph node region (stage I), or a single extralymphatic organ or site (stage IE) without nodal involvement. A single lymph node region can include one node or a group of adjacent nodes  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage II</strong> – Two or more nodal regions on the same side of the diaphragm (stage II), or stage I or II by nodal involvement with limited contiguous extranodal involvement (stage IIE).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage III</strong> – Lymph node involvement on both sides of the diaphragm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage IV</strong> – Diffuse or disseminated involvement of one or more extralymphatic organs (eg, liver, bone marrow, lung), with or without associated node involvement.</p><p></p><p>Noteworthy points for staging NHLs according to the Lugano system include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Constitutional symptoms</strong> – Systemic "B" symptoms (fever, sweats, weight loss) are <strong>not</strong> incorporated into the staging of NHL, in contrast with classic Hodgkin lymphoma (cHL), because they are not independent prognostic factors for patients with NHL. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extranodal involvement</strong> – The subscript "E" is used if limited extranodal extension is documented; multiple sites/more widespread extranodal disease is designated stage IV. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spleen</strong> – Disease involving the spleen is considered nodal, rather than extranodal. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bulky/large</strong> <strong>tumor masses</strong> – The Lugano classification requires a recording of the largest tumor diameter. Criteria for bulky disease vary by histology and no cutoff has been validated using modern treatment [<a href="#rid9">9,10</a>], but cutoffs of 6 cm and 6 to 10 cm are used for follicular lymphoma and DLBCL, respectively.</p><p></p><p>Most types of NHLs spread hematogenously, rather than by contiguous lymphatic extension (as occurs with cHL); as a result, disease stage is less important prognostically for NHL than for cHL. As an example, treatment of stage III and stage IV is generally very similar. Nevertheless, staging of NHL is important to identify patients with early-stage disease who can be treated with local therapy or with combined modality treatment (ie, chemotherapy plus radiation therapy). </p><p class="headingAnchor" id="H334141054"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Prognosis for patients with NHL is greatly affected by histopathology, but it is less influenced by clinical parameters such as age, extranodal disease, performance status, and stage (I/II versus III/IV). </p><p>Within specific NHL categories, prognosis is related to aspects of tumor cell biology, such as cytogenetics, immunophenotype, growth fraction, or cytokine production. Tumor burden is important prognostically and may affect treatment for NHL (eg, use of adjuvant radiotherapy to sites of bulky disease), but it may not be accurately reflected in the disease stage, which depends only upon the location and number of disease sites. </p><p>Prognostic instruments that can be valuable for NHL include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Prognostic Index</strong> <strong>(IPI) </strong>– The IPI  (<a class="graphic graphic_table graphicRef70850" href="/z/d/graphic/70850.html" rel="external">table 10</a>) has value with all categories of NHL. (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'International Prognostic Index'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-specific</strong> – Disease-specific prognostic scores incorporate variables of tumor biology for specific NHL variants, such as the Follicular Lymphoma International Prognostic Index (FLIPI)  (<a class="graphic graphic_table graphicRef55987" href="/z/d/graphic/55987.html" rel="external">table 11</a>) and the NK/T cell lymphoma prognostic index  (<a class="graphic graphic_table graphicRef67924" href="/z/d/graphic/67924.html" rel="external">table 12</a>). (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Follicular lymphoma IPI (FLIPI)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment-specific</strong> – Treatment-specific prognostic scores incorporate variables that reflect interactions among patient, tumor, and the therapeutic regimen [<a href="#rid24">24</a>]. An example is cell of origin analysis, which is associated with outcomes for patients with DLBCL treated with CHOP (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>). (See  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma", section on 'Cell of origin studies'</a>.)</p><p></p><p>Further discussion of prognosis for specific categories of NHL is presented separately. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse large B cell lymphoma (see  <a class="medical medical_review" href="/z/d/html/83821.html" rel="external">"Prognosis of diffuse large B cell lymphoma"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follicular lymphoma (see  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Prognosis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral T cell lymphoma (see  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified", section on 'Prognosis'</a>)</p><p></p><p class="headingAnchor" id="H81037638"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117911.html" rel="external">"Society guideline links: Lymphoma diagnosis and staging"</a>.)</p><p class="headingAnchor" id="H989824"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15492.html" rel="external">"Patient education: Lymphoma (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/694.html" rel="external">"Patient education: Follicular lymphoma in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/691.html" rel="external">"Patient education: Diffuse large B cell lymphoma in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H43"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of pretreatment evaluation </strong>– Management of the patient with newly diagnosed non-Hodgkin lymphoma (NHL) is based on histologic subtype  (<a class="graphic graphic_table graphicRef110240" href="/z/d/graphic/110240.html" rel="external">table 1</a>), disease stage  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 2</a>), and medical fitness. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical and laboratory evaluation</strong> – Evaluation includes (see <a class="local">'Clinical and laboratory evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History</strong> – Constitutional symptoms (fevers, sweats, weight loss), neurologic complaints, symptoms related to comorbid conditions (eg, heart, lung, kidney, liver disease), and performance status  (<a class="graphic graphic_table graphicRef58785 graphicRef72901" href="/z/d/graphic/58785.html" rel="external">table 3A-B</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Examination</strong> – Evaluation of lymph node-bearing areas, liver, spleen, and neurologic findings.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Testing includes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hematology</strong> – Complete blood count with differential </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Serum chemistries</strong> – Electrolytes, kidney and liver function tests, lactate dehydrogenase, uric acid </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Infectious</strong> – HIV testing (all patients) and hepatitis B and hepatitis C testing (selected patients) (see <a class="local">'Laboratory studies'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical testing</strong> – For selected patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac</strong> – Ejection fraction by echocardiogram or radionuclide ventriculogram for patients with heart disease or who may receive mediastinal radiation or anthracycline-based therapy. (See <a class="local">'Cardiac function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow (BM) </strong>– BM examination is obtained to (see <a class="local">'Bone marrow examination'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exclude systemic disease in a patient with apparent stage I disease </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Investigate unexplained cytopenias </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Central nervous system (CNS)</strong> – CNS should be evaluated for patients with neurologic findings, certain histologic categories (eg, highly aggressive subtypes, AIDS-related NHL), or clinical features (eg, epidural, bone marrow, testicular, paranasal sinus involvement, or ≥2 extranodal disease sites). Evaluation includes magnetic resonance imaging (MRI) and/or lumbar puncture (LP). (See <a class="local">'Central nervous system (CNS)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertility preservation</strong> – Fertility preservation, including sperm or fertilized oocyte preservation, should be discussed with patients of childbearing age. (See <a class="local">'Fertility preservation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Choice of imaging varies with the histologic category:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Positron emission tomography (PET)/computed tomography (CT)</strong> – PET/CT is preferred for staging most types of NHL, but some more indolent histologic types are variably PET-avid or non-avid, such as (see <a class="local">'Positron emission tomography (PET)'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Chronic lymphocytic leukemia/small lymphocytic lymphoma </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mycosis fungoides </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Marginal zone lymphoma</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Computed tomography </strong>– CT of chest, abdomen, and pelvis with intravenous contrast or oral contrast may be more useful for staging variably PET-avid categories (above) and for defining disease of any category that involves lymphadenopathy close to bowel or blood vessels. (See <a class="local">'Computed tomography (CT)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of specific sites</strong> – Special testing for involvement of gastrointestinal tract, bone, and genitourinary system is described above. (See <a class="local">'Evaluation of specific sites'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The Lugano classification  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 2</a>) uses clinical examination and PET/CT to stage NHL (see <a class="local">'Staging'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage I</strong> – Single lymph node region (stage I), or a single extralymphatic organ or site (stage IE) without nodal involvement  (<a class="graphic graphic_figure graphicRef55422" href="/z/d/graphic/55422.html" rel="external">figure 1</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage II</strong> – Two or more involved node regions on the same side of the diaphragm (stage II) or with localized involvement of an extralymphatic organ or site (stage IIE)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage III</strong> – Nodal involvement on both sides of the diaphragm </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage IV</strong> – Diffuse or disseminated involvement of one or more extralymphatic organs (eg, liver, bone marrow, lung), with or without associated lymph node involvement</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63:261.</a></li><li><a class="nounderline abstract_t">Cao X, Wang Y, Li P, et al. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021; 11:685706.</a></li><li><a class="nounderline abstract_t">Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136:699.</a></li><li><a class="nounderline abstract_t">Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48:1307.</a></li><li><a class="nounderline abstract_t">Viswanatha DS, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007; 60:1378.</a></li><li><a class="nounderline abstract_t">Spinelli JJ, Lai AS, Krajden M, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008; 122:630.</a></li><li><a class="nounderline abstract_t">Schöllkopf C, Smedby KE, Hjalgrim H, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008; 122:1885.</a></li><li><a class="nounderline abstract_t">Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010; 11:827.</a></li><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32:3048.</a></li><li><a class="nounderline abstract_t">Adams HJ, Kwee TC, de Keizer B, et al. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2014; 41:565.</a></li><li><a class="nounderline abstract_t">Rutherford SC, Yin J, Pederson L, et al. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol 2023; 41:336.</a></li><li><a class="nounderline abstract_t">Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004; 6:411.</a></li><li><a class="nounderline abstract_t">Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Radiology 2004; 232:823.</a></li><li><a class="nounderline abstract_t">Hernandez-Maraver D, Hernandez-Navarro F, Gomez-Leon N, et al. Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma. Br J Haematol 2006; 135:293.</a></li><li><a class="nounderline abstract_t">Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood 2008; 111:504.</a></li><li><a class="nounderline abstract_t">Freudenberg LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31:325.</a></li><li><a class="nounderline abstract_t">Kinahan PE, Fletcher JW. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR 2010; 31:496.</a></li><li><a class="nounderline abstract_t">Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51:25.</a></li><li><a class="nounderline abstract_t">Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101:3875.</a></li><li><a class="nounderline abstract_t">Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 2007; 110:652.</a></li><li><a class="nounderline abstract_t">Silverman JF, Geisinger KR, Raab SS, Stanley MW. Fine needle aspiration biopsy of the spleen in the evaluation of neoplastic disorders. Acta Cytol 1993; 37:158.</a></li><li><a class="nounderline abstract_t">Moriarty AT, Schwenk GR Jr, Chua G. Splenic fine needle aspiration biopsy in the diagnosis of lymphoreticular diseases. A report of four cases. Acta Cytol 1993; 37:191.</a></li><li><a class="nounderline abstract_t">Lee SM, Ryder WD, Clemons MJ, et al. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1999; 24:271.</a></li></ol></div><div id="topicVersionRevision">Topic 4696 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26566064" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : AASLD guidelines for treatment of chronic hepatitis B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34277431" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17338776" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613758" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rituximab-related viral infections in lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042694" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hepatitis C virus and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935132" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18271005" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatitis C infection and risk of malignant lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688564" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113771" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24281821" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35787017" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564152" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15273335" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032175" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Positron emission tomography/computed tomography: diagnostic accuracy in lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916746" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Imaging in staging of malignant lymphoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14647988" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : FDG-PET/CT in re-staging of patients with lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21147377" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20009002" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531812" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Utility of FDG-PET scanning in lymphoma by WHO classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17582800" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8465634" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fine needle aspiration biopsy of the spleen in the evaluation of neoplastic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8465640" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Splenic fine needle aspiration biopsy in the diagnosis of lymphoreticular diseases. A report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10455365" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
